| Budget Amount *help |
¥171,470,000 (Direct Cost: ¥131,900,000、Indirect Cost: ¥39,570,000)
Fiscal Year 2014: ¥31,070,000 (Direct Cost: ¥23,900,000、Indirect Cost: ¥7,170,000)
Fiscal Year 2013: ¥32,500,000 (Direct Cost: ¥25,000,000、Indirect Cost: ¥7,500,000)
Fiscal Year 2012: ¥33,930,000 (Direct Cost: ¥26,100,000、Indirect Cost: ¥7,830,000)
Fiscal Year 2011: ¥33,670,000 (Direct Cost: ¥25,900,000、Indirect Cost: ¥7,770,000)
Fiscal Year 2010: ¥40,300,000 (Direct Cost: ¥31,000,000、Indirect Cost: ¥9,300,000)
|
|---|
| Outline of Final Research Achievements |
We previously developed induced cancer stem cells (iCSCs). Based on this technology, we characterized the dynamics of CSCs and analyzed their interaction with non-CSCs. Specific aim of our project was to identify the molecules regulating the functions of CSCs and compounds targeting those molecules, leading to the development of the strategies to overcome therapeutic resistance of CSCs. We have identified: i) Imp3 as a master regulator for tumorigenesis of osteosarcoma CSCs, ii) the IGF signals which promote therapeutic resistance of CSCs and iii) CD44v as a functional molecule to reduce reactive oxygen species and to promote tumor growth and therapeutic resistance.
|
